UNSPSC 51422415: Hydrocortisone

This classification denotes an anti-inflammatory agent with the molecular formula C21H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WI4X0X7BPJ, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but generally known as hydrocortisone, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. The term HYDROCORTISONE is an International Non-Proprietary Name.

UNSPSC 51422415 Hydrocortisone is a Commodity code nominally identifying a specific pharmaceutical agent, but the recent state and local opportunities posted under this code do not align with hydrocortisone procurement. The single identified recent opportunity — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems, products unrelated to hydrocortisone's scope. This mismatch suggests either a data tagging error in the source or a jurisdiction's use of the code outside its intended pharmaceutical taxonomy. State and local procurement under this code shows minimal recent activity aligned with the code's nominal product.

Seminole County, Florida released the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement requires vendors to submit bids electronically, include all shipping and delivery costs, provide drug-free workplace certification and E-Verify compliance, and maintain workers' compensation and commercial general liability insurance. The contract carries an initial two-year term with a one-year renewal option and includes a three-month probationary period. The opportunity may be funded through FEMA, which introduces federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. Without additional recent opportunities under this code aligned with hydrocortisone or related corticosteroid pharmaceuticals, characterizing issuing-body patterns, geographic concentration, or procurement volume across state and local markets is not supported by the source.